David H. Bergstrom
Amministratore Delegato presso Bridge Therapeutics, Inc.
Posizioni attive di David H. Bergstrom
Società | Posizione | Inizio | Fine |
---|---|---|---|
Bridge Therapeutics, Inc.
Bridge Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bridge Therapeutics, Inc. is a pharmaceutical company. The firm specializes in chronic pain and opioid addiction. The company was founded by Greg Sullivan and is headquartered in Birmingham, AL. | Direttore/Membro del Consiglio | - | - |
Amministratore Delegato | 01/01/2018 | - |
Storia della carriera di David H. Bergstrom
Precedenti posizioni note di David H. Bergstrom
Società | Posizione | Inizio | Fine |
---|---|---|---|
NOVADEL PHARMA INC | Direttore operativo | 08/12/2006 | 31/01/2012 |
CARDINAL HEALTH, INC. | Direttore Tecnico/Scientifico/R&S | 01/01/1999 | 01/11/2006 |
Corporate Officer/Principal | 01/01/1999 | - | |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Direttore Tecnico/Scientifico/R&S | 01/01/1998 | 01/01/1999 |
Corporate Officer/Principal | 01/01/1998 | - | |
Hoechst Marion Roussel, Inc. | Corporate Officer/Principal | 01/01/1996 | 01/01/1998 |
Hoechst-Roussel Pharmaceuticals, Inc. | Corporate Officer/Principal | 01/01/1991 | 01/01/1996 |
Eurofins Advantar Laboratories, Inc.
Eurofins Advantar Laboratories, Inc. BiotechnologyHealth Technology Eurofins Advantar Laboratories, Inc. specializes in analytical development and formulation services for large molecule and small molecule programs, medical devices, and novel combination products. Its services include biophysical characterization, bimolecular and small molecules, FTE programs, data review support, regulatory and CMC consulting, litigation support and expert testimony, PAI audit and FDA response support. The company was founded by David F. Hale, John Alaimo, Richard A. Kenley, and Edward Foster in 2008 and is headquartered in San Diego, CA. | Direttore operativo | - | - |
ANTARES PHARMA, INC. | Corporate Officer/Principal | 19/11/2013 | - |
Formazione di David H. Bergstrom
University of Utah | Doctorate Degree |
University of Michigan | Graduate Degree |
Ferris State University (Michigan) | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 12 |
Posizioni
Corporate Officer/Principal | 5 |
Chief Operating Officer | 2 |
Chief Tech/Sci/R&D Officer | 2 |
Settori
Health Technology | 6 |
Consumer Services | 4 |
Distribution Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
CARDINAL HEALTH, INC. | Distribution Services |
Aziende private | 7 |
---|---|
NovaDel Pharma, Inc.
NovaDel Pharma, Inc. Pharmaceuticals: MajorHealth Technology NovaDel Pharma, Inc. engages in developing oral spray formulations for different types of drugs. It develops oral spray and pharmaceutical products for angina pectoris, insomia, migraine headaches, and disorders of the central nervous system. The company was founded in 1982 and is headquartered in Bridgewater, NJ. | Health Technology |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Health Technology |
Hoechst Marion Roussel, Inc. | |
Hoechst-Roussel Pharmaceuticals, Inc. | |
Antares Pharma, Inc.
Antares Pharma, Inc. Pharmaceuticals: MajorHealth Technology Antares Pharma, Inc. is a specialty pharmaceutical company, which engages in the development and commercialization of pharmaceutical products and technologies in targeted therapeutic areas. Its products include XYOSTED injection, OTREXUP injection for subcutaneous use, and Sumatriptan injection. The company was founded in February 1979 and is headquartered in Ewing, NJ. | Health Technology |
Eurofins Advantar Laboratories, Inc.
Eurofins Advantar Laboratories, Inc. BiotechnologyHealth Technology Eurofins Advantar Laboratories, Inc. specializes in analytical development and formulation services for large molecule and small molecule programs, medical devices, and novel combination products. Its services include biophysical characterization, bimolecular and small molecules, FTE programs, data review support, regulatory and CMC consulting, litigation support and expert testimony, PAI audit and FDA response support. The company was founded by David F. Hale, John Alaimo, Richard A. Kenley, and Edward Foster in 2008 and is headquartered in San Diego, CA. | Health Technology |
Bridge Therapeutics, Inc.
Bridge Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bridge Therapeutics, Inc. is a pharmaceutical company. The firm specializes in chronic pain and opioid addiction. The company was founded by Greg Sullivan and is headquartered in Birmingham, AL. | Health Technology |
- Borsa valori
- Insiders
- David H. Bergstrom
- Esperienza